StockData
Repligen Corp logo

Repligen Corp (RGEN) stock

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30133% above fair value
$162.18−0.60 (-0.37%)

Close on Nov 17, 2026Market cap $10.37BP/E –Yield –

Repligen enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Repligen's enterprise value was $8.93B on Nov 11, 2026, against $8.88B a year earlier. Over the last 5 years it ranged from $5.87B to $14.02B, with a median of $8.42B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$8.93B+5.4%
2025Dec 31, 2025$8.47B+16.4%
2024Dec 31, 2024$7.28B-22.5%
2023Dec 29, 2023$9.40B+6.5%
2022Dec 30, 2022$8.83B-37.0%
2021Dec 31, 2021$14.02B+47.2%
2020Dec 31, 2020$9.53B+122.0%
2019Dec 31, 2019$4.29B+102.2%
2018Dec 31, 2018$2.12B+49.4%
2017Dec 29, 2017$1.42B+60.6%
2016Dec 30, 2016$884.77M+0.1%
2015Dec 31, 2015$883.89M+44.5%
2014Dec 31, 2014$611.61M+64.5%
2013Dec 31, 2013$371.89M+158.5%
2012Dec 31, 2012$143.88M+151.1%
2011Dec 30, 2011$57.29M-56.5%
2010Dec 31, 2010$131.70M–

More Repligen figures

See a number that looks wrong?